ArticleThe oncologist2025
Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe optimal treatment strategy for limited-stage small cell esophageal carcinoma (LS-SCEC) remains uncertain. This study aimed to retrospectively evaluate the efficacy of perioperative therapy in these patients. MATERIALS AND
methodsBetween June 2005 and November 2022, 156 patients with LS-SCEC who underwent esophagectomy were included in this study. The primary endpoint was overall survival (OS), and secondary endpoints included disease-free survival (DFS) and postoperative complications. Prognostic factors were analyzed using univariate and multivariate Cox regression models, as well as propensity score matching.
resultsOf the 156 patients, 33 (21.2%) patients received neoadjuvant chemotherapy, 76 (48.7%) underwent adjuvant chemotherapy, and 13 (8.3%) received adjuvant chemoradiotherapy. Post-surgery, 33 (21.2%) patients were classified as stage I, 40 (25.6%) as stage II, 61 (39.1%) as stage III, and 22 (14.1%) as stage IV. The median OS was 21.0 months, with 5-year OS and DFS rates of 25.9% and 21.9%, respectively. Multivariate analysis identified clinical T stage (P = .049), neural invasion (P = .002), N stage (P = .006), and adjuvant therapy (P = .001) as independent prognostic factors. Neoadjuvant chemotherapy significantly improved OS, with a 5-year OS rate of 37.7% compared to 0.0% in the non-neoadjuvant chemotherapy group (P < .001). Across the cohort, adjuvant therapy enhanced both OS and DFS.
conclusionsPerioperative therapy is crucial for LS-SCEC management. Neoadjuvant chemotherapy improves OS in patients with LS-SCEC. Adjuvant chemotherapy is recommended almost for all patients with LS-SCEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.